
    
      Participants who were randomized to the placebo arm and completed all scheduled study
      procedures were eligible to receive active SOF+RBV in open-label Study GS-US-334-0109.

      Participants who do not achieve sustained virologic response (SVR) were eligible for
      enrollment in the Sequence Registry Study GS-US-248-0123. The purpose of the Sequence
      Registry Study is to monitor the persistence of resistant mutations for up to 3 years.

      Participants who achieved SVR were eligible for enrollment in the SVR Registry Study
      GS-US-248-0122. The purpose of the SVR Registry Study is to evaluate durability of SVR for up
      to 3 years after treatment.
    
  